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BACKGROUND: To analyse the correlation between pre-treatment plasma fibrinogen levels and clinical–pathological parameters in
patients with endometrial cancer and to assess the value of plasma fibrinogen as a prognostic parameter.
METHODS: Within a retrospective multi-centre study, the records of 436 patients with endometrial cancer were reviewed and
pre-treatment plasma fibrinogen levels were correlated with clinical–pathological parameters and patients’ survival.
RESULTS: The mean (s.d.) pre-treatment plasma fibrinogen level was 388.9 (102.4) mg per 100ml. Higher plasma fibrinogen levels
were associated with advanced tumour stage (FIGO I vs II vs III and IV, P¼0.002), unfavourable histological subtype (endometrioid vs
non-endometrioid histology, P¼0.03), and higher patients’ age (p67 years vs 467 years, P¼0.04), but not with higher histological
grade (G1 vs G2 vs G3, P¼0.2). In a multivariate analysis, tumour stage (Po0.001 and Po0.001), histological grade (P¼0.009 and
P¼0.002), patients’ age (P¼0.001 and Po0.001), and pre-treatment plasma fibrinogen levels (P¼0.04 and P¼0.02) were
associated with disease-free and overall survival, respectively.
CONCLUSION: Plasma fibrinogen levels can be used as an independent prognostic parameter for the disease-free and overall survival of
patients with endometrial cancer.
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The association between cancer and haemostasis, as well as
inflammation, is widely accepted (Dvorak, 1986; Andreasen et al,
2000; Balkwill and Mantovani, 2001; Coussens and Werb, 2002). A
number of procoagulant and fibrinolytic factors have been found
to be overexpressed in malignant human and animal tumour cells
(Dvorak, 1986; Brown et al, 1988; Bardos et al, 1996).
One of these factors is fibrinogen, a plasma glycoprotein that is
mainly responsible for the formation of a meshwork of fibrin
monomers that consolidates an initial platelet plug into a solid
haemostatic clot (Hantgan et al, 2001). As one of several acute-
phase reactant proteins, it rises during systemic inflammation and
tissue injury (Holm and Godal, 1984). Fibrinogen is mainly
produced by hepatocytes; however, extrahepatical synthesis by
epithelial cells and tumour cells has been described (Lawrence and
Simpson-Haidaris, 2004).
Extensive studies on human and animal tumour biology indicate
a specific link between fibrinogen and the progressive and
metastatic behaviour of tumour cells (Palumbo et al, 2000, 2002,
2005; Simpson-Haidaris and Rybarczyk, 2001). Recent studies
showed a correlation between elevated plasma fibrinogen levels
and tumour progression in patients with gastric (Lee et al, 2004;
Yamashita et al, 2005, 2006), oesophageal (Takeuchi et al, 2007),
non-small-cell lung (Jones et al, 2006), breast, ovarian (Von
Tempelhoff et al, 2000), and cervical cancer (Polterauer et al,
2009).
Regarding endometrial cancer, a hypercoagulable state is known
to be associated with advanced tumour stage and higher
histological grade (Von Tempelhoff et al, 2000). In a small series
of patients with endometrial cancer (n¼70), pre-treatment plasma
fibrinogen levels correlated with tumour stage but not with
patients’ survival (Von Tempelhoff et al, 2000). The aim of
this study was to analyse the correlation between pre-treatment
plasma fibrinogen levels and clinical–pathological parameters
in patients with endometrial cancer and to assess the value of
plasma fibrinogen as a prognostic parameter in a large multi-
centre trial.
MATERIALS AND METHODS
Patients
A total of 436 consecutive patients with endometrial cancer,
treated at the Departments of Obstetrics and Gynaecology at the
Medical University of Vienna (n¼360) and at the Landeskran-
kenhaus Klagenfurt (n¼76) between December 1995 and June
2008, were enrolled in this study. Clinical and laboratory data were
extracted retrospectively from patient files.
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sClinical management
Diagnosis of endometrial cancer was established by dilation and
curettage. Subsequently, patients were surgically staged according
to the International Federation of Gynaecology and Obstetrics
(FIGO)/American Joint Committee on Cancer (AJCC) classification
system.
Hysterectomy, bilateral salpingo-oophorectomy, cytological
examination of peritoneal fluid, and biopsy of any suspicious
intraperitoneal or retroperitoneal lesions were performed. Pelvic
and paraaortic lymphadenectomy was conducted, except for
tumour stage Ia and Ib with histological grades 1 and 2 and
endometrioid histology. In patients with intermediate-risk or
high-risk disease, adjuvant radiotherapy was provided according
to standardised treatment protocols (Nag et al, 2000). A regimen of
adjuvant chemotherapy using carboplatin/paclitaxel was used in
selected patients with advanced disease.
At 3 months after completion of primary therapy, the first
follow-up visit was scheduled. Patients had follow-up visits at
3-month intervals for the following 3 years, including inspection,
vaginal–rectal palpation, and serum tumour marker evaluation.
In the fourth and fifth year, visits were scheduled bi-annually, and
once a year from the sixth to the tenth year after primary therapy.
When patients did not present for scheduled follow-up visits, they
were contacted by administrative personnel or nurses. When any
clinically suspicious finding and/or tumour marker elevation was
observed, computed tomography was performed. Recurrent
disease was diagnosed histologically or by the presence of a
measurable lesion on computed tomography.
Measurement of fibrinogen and other laboratory
parameters
The analysis of plasma fibrinogen levels, serum CA 125, white
blood cell count, and platelet count was routinely performed
before therapy. Blood samples (citrated plasma) were obtained by
peripheral venous puncture before surgery. Plasma fibrinogen
levels were determined by the Clauss method (Clauss, 1957) using
clotting reagents from Diagnostica Stago (Asnieres, France). The
manufacturer claims an intra-assay variability of 3.5%. Plasma
fibrinogen levels between 180 and 390mg per 100ml were defined
as normal. For serum CA 125, a cutoff value of 40Uml
–1has been
determined, as described previously (Hsieh et al, 2002). Cutoff
values for white blood cell count (1 10
10ml
–1) and platelet count
(450000ml
–1) were used according to standardised guidelines for
leukocytosis and thrombocytosis.
Statistical analysis
Values are given as means (s.d.). The t-tests and one-way ANOVA
were used to compare fibrinogen plasma levels and clinical–
pathological parameters. Survival probabilities were calculated by
the product limit method of Kaplan–Meier. Differences between
groups were tested using the log-rank test. Results were analysed
for the end point of disease-free and overall survival. Events were
defined as death or progression at the time of the last follow-up
visit. Survival times of disease-free patients or patients with stable
disease were censored with the last follow-up-date, and patients with
death causes other than endometrial cancer were censored with the
date of death. Univariate and multivariate Cox regression models for
disease-free and overall survival were performed, comprising FIGO
tumour stage (FIGO I vs FIGO II vs FIGO III and IV), histological
grade (G1 vs G2 vs G3), histological subtype (endometrioid
adenocarcinoma vs non-endometrioid carcinoma, such as serous
and clear cell carcinoma), and pre-treatment plasma fibrinogen
levels. The P-values of o0.05 were considered statistically
significant. We used the statistical software SPSS 16.0 for Mac
(SPSS 16.0.1, SPSS Inc., Chicago, IL, USA) for statistical analysis.
Institutional review board
This study was approved by our institutional review board, by the
Ethics-Committee of the Medical University of Vienna, and by the
Vienna General Hospital (AKH).
RESULTS
Patients’ characteristics are given in Table 1. The mean (s.d.) pre-
treatment plasma fibrinogen level was 388.9 (102.4) mg per 100ml.
Lymph node status was available in 180 patients. Lymph node
involvement was noted in 26 patients. In all, 168 patients received
adjuvant radiotherapy, and 35 patients received adjuvant
chemotherapy.
The correlation between pre-treatment plasma fibrinogen levels
and clinical–pathological parameters is given in Table 2. Higher
pre-treatment plasma fibrinogen levels were associated with
advanced tumour stage, unfavourable histological subtype, and
higher patients’ age, but not with higher histological grade. Pre-
treatment plasma fibrinogen levels were significantly associated
with serum CA 125, white blood cell count, and platelet count
(Table 2).
In a univariate analysis, tumour stage, histological grade,
histological subtype, patients’ age, and pre-treatment plasma
fibrinogen levels were associated with disease-free and overall
survival. In a multivariate analysis, tumour stage, histological
grade, patients’ age, and pre-treatment plasma fibrinogen levels
Table 1 Patients’ characteristics
Parameter
Number (%)
or mean (s.d.)
Total number of patients enrolled 436
Age at first diagnosis (years) 66.9 (11.2)
Tumour stage
FIGO Ia 69 (15.8)
FIGO Ib 191 (43.8)
FIGO Ic 67 (15.4)
FIGO IIa 17 (3.9)
FIGO IIb 23 (5.3)
FIGO IIIa 29 (6.7)
FIGO IIIb 4 (0.9)
FIGO IIIc 24 (5.5)
FIGO IVa 3 (0.7)
FIGO IVb 9 (2.0)
Histological grade
G1 190 (43.6)
G2 151 (34.6)
G3 95 (21.8)
Histological subtype
Endometrioid histology 408 (93.6)
Non-endometrioid histology (clear cell, serous carcinoma) 28 (6.4)
Time of follow-up (months) 36.1 (31.1)
Recurrence status
Number of patients with recurrent disease 76 (17.4)
Time to recurrent disease (months) 19.9 (18.9)
Status at last observation
Disease-free 340 (78.0)
Stable disease 22 (5.0)
Progressive disease 42 (9.6)
Tumour-related death 20 (4.6)
Death related to other causes 12 (2.8)
Abbreviation: FIGO¼International Federation of Gynecology and Obstetrics.
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the univariate and multivariate Cox regression models and
log-rank tests with respect to overall and disease-free survival
are shown in Table 3. It is noteworthy that when patients were
grouped according to the mean plasma fibrinogen level, patients
with plasma fibrinogen levels of o388.9 and X388.9mg per 100ml
had a 5-year disease-free survival rate of 80 and 66% (P¼0.01) and
an overall survival rate of 84 and 74% (P¼0.005), respectively
(Figures 1 and 2). By comparing pre-treatment plasma fibrinogen
levels between patients with and without recurrent disease in each
FIGO tumour stage separately, we could show a significant
difference within the group of FIGO tumour stage III and IV
(P¼0.03), but not within the group of FIGO tumour stage I
(P¼0.3) and II (P¼0.5).
DISCUSSION
A strong association between haemostasis and tumour biology has
been described previously (Dvorak, 1986; Von Tempelhoff et al,
2000; Balkwill and Mantovani, 2001; Coussens and Werb, 2002). In
this retrospective multi-centre trial, we determined the effect of
Table 2 Mean plasma fibrinogen levels in patients with endometrial
cancer broken down by clinical–pathological and laboratory parameters
Mean (s.d.) plasma
fibrinogen levels
(mg per 100ml) P-value
FIGO tumour stage
a 0.002
I 379.7 (99.6)
II 400.4 (87.8)
III and IV 425.8 (114.9)
Histological grade
a 0.2
G1 385.8 (104.8)
G2 383.2 (99.3)
G3 405.6 (100.9)
Histological subtype
b 0.03
Endometrioid histology 386.1 (98.5)
Non-endometrioid histology 429.1 (144.8)
Age
b 0.04
p67 years 379.3 (100.3)
467 years 398.9 (103.8)
CA 125
b 0.02
p40Uml
–1 399.6 (87.7)
440Uml
–1 432.2 (124.8)
White blood cells
b 0.002
p1 10
10ml
–1 384.2 (97.4)
41 10
10ml
–1 442.7 (129.6)
Platelets
b o0.001
p450000ml
–1 385.3 (96.9)
4450000ml
–1 563.0 (163.04)
Abbreviation: FIGO¼International Federation of Gynecology and Obstetrics.
aOne-way ANOVA.
bIndependent two-sided t-test.
Table 3 Univariate and multivariate survival analysis
Disease-free survival Overall survival
Univariate analysis
a Multivariate analysis
b Univariate analysis
a Multivariate analysis
b
P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI)
Tumour stage
c o0.001 — o0.001 2.2 (1.7–2.8) o0.001 — o0.001 2.1 (1.6–2.8)
Histological grade
d o0.001 — 0.04 1.4 (1.02–2.0) o0.001 — 0.002 1.8 (1.2–2.5)
Histological subtype
e o0.001 — 0.1 1.7 (0.9–3.4) 0.002 — 0.6 1.3 (0.6–2.8)
Age o0.001 1.1 (1.0–1.1) 0.001 1.04 (1.02–1.1) o0.001 1.1 (1.0–1.1) o0.001 1.1 (1.03–1.1)
Plasma fibrinogen levels
f 0.002
b 1.4 (1.1–1.8) 0.04 1.3 (1.01–1.6) 0.001 1.4 (1.1–1.8) 0.01 1.4 (1.1–1.2)
Abbreviation: HR (95% CI)¼hazard ratio (95% confidence interval).
aKaplan–Meier analysis.
bMultivariate Cox regression model.
cFIGO I vs FIGO II vs FIGO III and IV.
dG1 vs G2
vs G3.
eEndometrioid vs non-endometrioid histology.
fPlasma fibrinogen levels per 100 units.
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Figure 1 Kaplan–Meier curves for disease-free survival broken down by
the mean plasma fibrinogen level.
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Figure 2 Kaplan–Meier curves for overall survival broken down by the
mean plasma fibrinogen level.
Plasma fibrinogen levels in patients with endometrial cancer
V Seebacher et al
954
British Journal of Cancer (2010) 102(6), 952–956 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
spre-treatment plasma fibrinogen levels on endometrial cancer in a
large series of patients. By correlating pre-treatment plasma
fibrinogen levels with clinical–pathological parameters, we could
show a significant association between elevated plasma fibrinogen
levels and advanced tumour stage.
These findings might be explained by hyperfibrinogenaemia
induced by an inflammatory reaction to tumour growth and a
hypercoagulable state in cancer patients (Gouin-Thibault et al, 2001;
Coussens and Werb, 2002). Other studies describe the endogenous
production of fibrinogen by tumour cells themselves (Lee et al,
1996; Lawrence and Simpson-Haidaris, 2004; Sahni et al, 2008).
Fibrinogen and its degradation product fibrin seem to encase
tumour cells and are capable of binding numerous cell types and
growth factors, and exert an effect as a bridge between tumour and
epithelial cells, thus providing structure to the tumour stroma and
altering invasive potential (Dvorak et al, 1983; Dvorak, 1986;
Costantini et al, 1991; Simpson-Haidaris and Rybarczyk, 2001).
Through an interaction with fibroblast growth factor-2 (FGF-2) and
vascular endothelial growth factor (VEGF), fibrinogen promotes
angiogenesis and tumour cell growth (Sahni and Francis, 2000;
Sahni et al, 2006, 2008). Another interesting research question
would be to compare plasma fibrinogen levels before surgery, after
surgery, during follow-up, and in an eventual recurrent disease
situation. These questions cannot be answered by our present study,
as only pre-treatment plasma fibrinogen levels were determined.
Not only tumour growth but also the metastatic potential of
tumour cells seems to be influenced by fibrinogen, as could be
showed in mice model studies (Palumbo et al, 2000, 2002, 2005).
In our study, we could show a significant correlation between
pre-treatment plasma fibrinogen levels and pre-treatment CA 125
levels. As CA 125 has been associated with lymphatic tumour cell
spread in patients with endometrial cancer (Hsieh et al, 2002), our
results seem to underline a possible functional link between
fibrinogen and metastasis. Fibrinogen seems to stabilise tumour-
associated platelets building microthrombi, which exert an effect
as a physical barrier, preventing adherence of natural killer cells,
monocytes, and lymphocytes to tumour cells. By protecting
tumour cells against the innate immune system, fibrinogen
enhances their metastatic potential (Palumbo et al, 2000, 2002,
2005; Biggerstaff et al, 2006, 2008).
The most interesting result of our study was the prognostic value
of pre-treatment plasma fibrinogen levels regarding patients’
survival. The prognosis of patients with endometrial cancer is
primarily determined by tumour stage, histological grade, histolo-
gical subtype, and patients’ age (Creasman et al, 2001; Jolly et al,
2006; Fujimoto et al, 2009). Only limited data exist on prognostic
serum tumour markers in patients with endometrial cancer, such as
CA 125 and C-reactive protein (Dotters, 2000; Schmid et al, 2007).
An association between blood rheology and prognosis in patients
with gynaecological malignancy has previously been reported (Von
Tempelhoff et al, 2000). Fibrinogen is associated with high plasma
viscosity; it promotes aggregation of red blood cells and decreases
cell deformability, resulting in reduced blood flow and oxygen
transport capacity (Lowe, 1994). Low oxygenation of tumour tissue
has been shown to be indicative of resistance to radiotherapy and
poor prognosis on overall survival in cervical cancer (Hockel et al,
1996; Gundersen and Palmer, 2008).
One of the reviewers of this paper pointed us towards another
unusual but interesting analysis. We compared pre-treatment
plasma fibrinogen levels between non-recurrent and recurrent
groups of patients in each FIGO tumour stage. A significant
difference was only shown for patients with advanced stage, but not
for early-stage disease. These findings are interesting, but do
not change the conclusions of our study, as the multi-
variate Cox regression analysis confirmed the independence of the
association between plasma fibrinogen levels and patients’ survival.
Presumably in early FIGO tumour stages, the number of patients
with recurrent disease is too small for showing a statistically
significant difference.
Owing to early diagnosis of endometrial cancer, the overall
prognosis of patients is relatively good compared with other
gynaecological malignancies. Nevertheless, it is important to identify
prognostic parameters in selecting patients for adjuvant therapy to
avoid over-treatment. Along with pre-treatment plasma fibrinogen
levels, the established prognostic parameters, namely, tumour stage,
histological grade, and patients’ age, were found to be independently
associated with survival. The majority of recurrence occurs within
36 months after diagnosis, which is covered by the follow-up time of
the patients involved in our study (Fung-Kee-Fung et al,2 0 0 6 ) .
In summary, our results show that plasma fibrinogen level is an
independent prognostic parameter in patients with endometrial
cancer. By showing a correlation between higher pre-treatment
plasma fibrinogen levels and advanced tumour stage, we provide
some insight into the possible functional properties of fibrinogen.
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